OVID stock icon

Ovid Therapeutics

1.03 USD
-0.03
2.83%
At close Dec 5, 4:00 PM EST
After hours
1.03
+0.00
0.00%
1 day
-2.83%
5 days
-7.21%
1 month
-17.60%
3 months
-9.65%
6 months
-66.56%
Year to date
-68.98%
1 year
-68.31%
5 years
-74.19%
10 years
-91.59%
 

About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

Employees: 25

0
Funds holding %
of 6,790 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

262% more call options, than puts

Call options by funds: $47K | Put options by funds: $13K

107% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 15

54% more capital invested

Capital invested by funds: $29.7M [Q2] → $45.8M (+$16.1M) [Q3]

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

1% more funds holding

Funds holding: 73 [Q2] → 74 (+1) [Q3]

0.31% more ownership

Funds ownership: 54.35% [Q2] → 54.66% (+0.31%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
191%
upside
Avg. target
$3
191%
upside
High target
$3
191%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
45% 1-year accuracy
105 / 232 met price target
191%upside
$3
Buy
Reiterated
4 Dec 2024
HC Wainwright & Co.
Raghuram Selvaraju
45% 1-year accuracy
105 / 232 met price target
191%upside
$3
Buy
Reiterated
30 Sept 2024

Financial journalist opinion

Negative
Zacks Investment Research
3 weeks ago
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago.
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of Meg Alexander to President and Chief Operating Officer (COO). Alexander will work in collaboration with Ovid's leadership team to advance Ovid's development pipeline of potential disease-halting neurotherapeutics and define and execute its go-forward strategy.
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
Positive
Zacks Investment Research
3 months ago
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Neutral
Accesswire
3 months ago
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm
Neutral
Accesswire
3 months ago
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
Neutral
Accesswire
3 months ago
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
Neutral
Accesswire
3 months ago
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
Neutral
Accesswire
3 months ago
Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm
Neutral
Accesswire
3 months ago
Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm
Neutral
Accesswire
3 months ago
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
Charts implemented using Lightweight Charts™